Piervi is an MD PhD also trained as a psychiatrist. He has been working full time on translational research since 1988. His particular field of expertise is the pathophysiology of behavior and in particular addiction, which he has been studying for 25 years. From 2007 to 2017, he was the director of the Neurocentre Magendie (INSERM, U1215) in Bordeaux. The role of pregnenolone as a signaling specific allosteric inhibitor of the CB1 has been discovered by his research group.
He cofounded Aelis Farma and was acting CSO of the company until his appointment as CEO of the company in December 2017. Previous to Aelis Farma, he cofounded two other biotech companies (Fluofarma and Alienor Farma), the former specialized in High Content Screening and the latter in the development of an anticancer drug. These two previous companies have given him a solid background in entrepreneurship and drug development.